Monitoring Circulating Tumor Cells May Further Personalized Cancer Treatment Interview with:

Dr. Elodie Sollier
Chief Scientific Officer at Vortex Biosciences What is the background for this study? What are the main findings?

Response: Circulating Tumor Cell (CTC) burden may be a useful biomarker of response to targeted therapy in PDX (Patient Derived Xenograft) mouse models. Vortex Biosciences’ technology has been proven to enrich CTCs from human blood, but use of the technology with mouse blood had not yet been explored. In this poster, human CTCs are isolated with both high efficiency and purity from xenograft model of breast cancer using Vortex’s technology. Circulating Tumor Cell enumeration increased as the tumor burden increased in the mouse demonstrating its utility as a biomarker for drug treatment response. What should clinicians and patients take away from your report?


  • Human Circulating Tumor Cell enrichment, enumeration and characterization from mouse blood can be achieved using Vortex’s technology.
  • Isolation of CTCs for enumeration and characterization from either PDX (Patient Derived Xenograft) and/or CDX (CTC Derived Xenograft) models seems achievable.
  • Patients may eventually have the option of exploring potential drug treatments and understanding their impact on the tumor burden and cancer cells before electing to go forward with a treatment. This should increase the effectiveness of drug treatments. What recommendations do you have for future research as a result of this study?

Response: Future work will focus on Circulating Tumor Cells isolated from mice implanted with patient-derived xenograft (PDX) and their response to drug therapy. Information gathered from these studies should facilitate both the discovery of new therapeutic targets and the development of personalized medicine. Is there anything else you would like to add?

Response: The Vortex technology offers a viable path for both creating CDX models by enriching Circulating Tumor Cells from human blood and for understanding drug treatment in PDX and CDX models by enriching and enumerating CTCs from mouse blood. Thank you for your contribution to the community.

Citation: Abstract presented at the 2016 AACR meeting

Vortex technology for label-free enrichment of CTC from mouse xenograft models

Kyra Heirich1, Melanie M. Triboulet1, Corinne M. Renier2, Vishnu C. Ramani1, Elodie Sollier2, Stefanie S. Jeffrey1.1Stanford University, Stanford, CA;2Vortex Biosciences Inc., Menlo Park, CA

Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.

More Medical Research Interviews on

[wysija_form id=”5″]